Search

Your search keyword '"Wei, Feixue"' showing total 18 results
Start Over Author "Wei, Feixue" Search Limiters Full Text
18 results on '"Wei, Feixue"'

1. Incidence and Clearance of Anal Human Papillomavirus Infection in 16 164 Individuals, According to Human Immunodeficiency Virus Status, Sex, and Male Sexuality: An International Pooled Analysis of 34 Longitudinal Studies.

Author

Wei, Feixue, Goodman, Marc T, Xia, Ningshao, Zhang, Jun, Giuliano, Anna R, D'Souza, Gypsyamber, Hessol, Nancy A, Schim van der Loeff, Maarten F, Dai, Jianghong, Neukam, Karin, de Pokomandy, Alexandra, Poynten, I Mary, Geskus, Ronald B, Burgos, Joaquin, Etienney, Isabelle, Moscicki, Anna-Barbara, Donà, Maria Gabriella, Gillison, Maura L, Nyitray, Alan G, Nowak, Rebecca G, Yunihastuti, Evy, Zou, Huachun, Hidalgo-Tenorio, Carmen, Phanuphak, Nittaya, Molina, Jean-Michel, Schofield, Alice M, Kerr, Stephen, Fan, Song, Lu, Yong, Ong, Jason J, Chikandiwa, Admire T, Teeraananchai, Sirinya, Squillace, Nicola, Wiley, Dorothy J, Palefsky, Joel M, Georges, Damien, Alberts, Catharina J, and Clifford, Gary M

Subjects
Cancer, Infectious Diseases, Behavioral and Social Science, Sexually Transmitted Infections, Clinical Research, Sexual and Gender Minorities (SGM/LGBT*), Prevention, HIV/AIDS, Aetiology, 2.2 Factors relating to the physical environment, Infection, Good Health and Well Being, Male, Humans, Female, Homosexuality, Male, Human Papillomavirus Viruses, Papillomavirus Infections, HIV Infections, Incidence, Sexual and Gender Minorities, Sexual Behavior, Anal Canal, Anus Diseases, Longitudinal Studies, Anus Neoplasms, Human papillomavirus 16, HIV, Papillomaviridae, HPV, anus, incidence, clearance, Biological Sciences, Medical and Health Sciences, Microbiology
Abstract

BackgroundUnderstanding the natural history of anal high-risk human papillomavirus (hrHPV) infection is key for designing anal cancer prevention programs but has not been systematically characterized.MethodsWe reanalyzed data from 34 studies including 16 164 individuals in 6 risk groups defined by human immunodeficiency virus (HIV) status, sex, and male sexuality: men who have sex with men (MSM) and people with HIV (MSMWH), HIV-negative MSM, women with HIV (WWH), HIV-negative women, men who have sex with women (MSW) with HIV (MSWWH), and HIV-negative MSW. We used Markov models to estimate incidence and clearance of 13 hrHPV types and their determinants.ResultsHuman papillomavirus (HPV) 16 had the highest incidence-clearance ratio of the hrHPV types. MSMWH had the highest hrHPV incidence (eg, 15.5% newly HPV-16 infected within 2 years), followed by HIV-negative MSM (7.5%), WWH (6.6%), HIV-negative women (2.9%), MSWWH (1.7%), and HIV-negative MSW (0.7%). Determinants of HPV-16 incidence included HIV status and number of sexual partners for MSM, women, and MSW, and anal sex behavior for MSM only. HPV-16 clearance was lower for people with HIV (PWH) and lower for prevalent than incident infection. Among MSM, increasing age was associated with lower clearance of prevalent, but not incident, HPV-16 infection.ConclusionsThis robust and unifying analysis of anal hrHPV natural history is essential to designing and predicting the impact of HPV vaccination and HPV-based screening programs on anal cancer prevention, particularly in MSM and PWH. Importantly, it demonstrates the higher carcinogenic potential of longstanding anal prevalent hrHPV infection than more recent incident infection.

Published
2023

2. Age-Specific Prevalence of Anal and Cervical Human Papillomavirus Infection and High-Grade Lesions in 11 177 Women by Human Immunodeficiency Virus Status: A Collaborative Pooled Analysis of 26 Studies.

Author

Wei, Feixue, Xia, Ningshao, Ocampo, Rebeca, Goodman, Marc T, Hessol, Nancy A, Grinsztejn, Beatriz, Ortiz, Ana P, Zhao, Fanghui, Kojic, Erna M, Kaul, Rupert, Heard, Isabelle, Morhason-Bello, Imran O, Moscicki, Anna-Barbara, de Pokomandy, Alexandra, Palefsky, Joel M, Rodrigues, Luana LS, Dube Mandishora, Racheal S, Ramautarsing, Reshmie A, Franceschi, Silvia, Godbole, Sheela V, Tso, Fernanda K, Menezes, Lynette J, Lin, Chunqing, and Clifford, Gary M

Subjects
Cervix Uteri, Humans, Papillomaviridae, HIV, Papillomavirus Infections, HIV Infections, Anus Neoplasms, Prevalence, Age Factors, Adolescent, Adult, Anal Canal, Uterine Cervical Neoplasms, Female, Human papillomavirus 16, Early Detection of Cancer, Young Adult, Squamous Intraepithelial Lesions, Human Papillomavirus Viruses, HPV, anus, cervix, women, Cancer, Prevention, Sexually Transmitted Infections, Infectious Diseases, HIV/AIDS, Cervical Cancer, Aetiology, 2.2 Factors relating to the physical environment, Infection, Good Health and Well Being, Biological Sciences, Medical and Health Sciences, Microbiology
Abstract

BackgroundAge-specific data on anal, and corresponding cervical, human papillomavirus (HPV) infection are needed to inform female anal cancer prevention.MethodsWe centrally reanalyzed individual-level data from 26 studies reporting HPV prevalence in paired anal and cervical samples by human immunodeficiency virus (HIV) status and age. For women with HIV (WWH) with anal high-grade squamous intraepithelial lesions or worse (HSIL+), we also investigated concurrent cervical cytopathology.ResultsIn HIV-negative women, HPV16 prevalence decreased significantly with age, both at anus (4.3% at 15-24 years to 1.0% at ≥55 years; ptrend = 0.0026) and cervix (7.4% to 1.7%; ptrend < 0.0001). In WWH, HPV16 prevalence decreased with age at cervix (18.3% to 7.2%; ptrend = 0.0035) but not anus (11.5% to 13.9%; ptrend = 0.5412). Given anal HPV16 positivity, concurrent cervical HPV16 positivity also decreased with age, both in HIV-negative women (ptrend = 0.0005) and WWH (ptrend = 0.0166). Among 48 WWH with HPV16-positive anal HSIL+, 27 (56%) were cervical high-risk HPV-positive, including 8 with cervical HPV16, and 5 were cervical HSIL+.ConclusionsAge-specific shifts in HPV16 prevalence from cervix to anus suggest that HPV infections in the anus persist longer, or occur later in life, than in the cervix, particularly in WWH. This is an important consideration when assessing the utility of cervical screening results to stratify anal cancer risk.

Published
2023

3. Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination:A systematic review and meta-analysis

Author

Steinberg, Julia, Hughes, Suzanne, Hui, Harriet, Allsop, Matthew J., Egger, Sam, David, Michael, Caruana, Michael, Coxeter, Peter, Carle, Chelsea, Onyeka, Tonia, Rewais, Isabel, Monroy Iglesias, Maria J., Vives, Nuria, Wei, Feixue, Abila, Derrick Bary, Carreras, Giulia, Santero, Marilina, O'Dowd, Emma L., Lui, Gigi, Tolani, Musliu Adetola, Mullooly, Maeve, Lee, Shing Fung, Landy, Rebecca, Hanley, Sharon J.B., Binefa, Gemma, McShane, Charlene M., Gizaw, Muluken, Selvamuthu, Poongulali, Boukheris, Houda, Nakaganda, Annet, Ergin, Isil, Moraes, Fabio Ynoe, Timilshina, Nahari, Kumar, Ashutosh, Vale, Diama B., Molina-Barceló, Ana, Force, Lisa M., Campbell, Denise Joan, Wang, Yuqing, Wan, Fang, Baker, Anna Lisa, Singh, Ramnik, Salam, Rehana Abdus, Yuill, Susan, Shah, Richa, Lansdorp-Vogelaar, Iris, Yusuf, Aasim, Aggarwal, Ajay, Murillo, Raul, Torode, Julie S., Kliewer, Erich V., Bray, Freddie, Chan, Kelvin K.W., Peacock, Stuart, Hanna, Timothy P., Ginsburg, Ophira, Van Hemelrijck, Mieke, Sullivan, Richard, Roitberg, Felipe, Ilbawi, André M., Soerjomataram, Isabelle, Canfell, Karen, Steinberg, Julia, Hughes, Suzanne, Hui, Harriet, Allsop, Matthew J., Egger, Sam, David, Michael, Caruana, Michael, Coxeter, Peter, Carle, Chelsea, Onyeka, Tonia, Rewais, Isabel, Monroy Iglesias, Maria J., Vives, Nuria, Wei, Feixue, Abila, Derrick Bary, Carreras, Giulia, Santero, Marilina, O'Dowd, Emma L., Lui, Gigi, Tolani, Musliu Adetola, Mullooly, Maeve, Lee, Shing Fung, Landy, Rebecca, Hanley, Sharon J.B., Binefa, Gemma, McShane, Charlene M., Gizaw, Muluken, Selvamuthu, Poongulali, Boukheris, Houda, Nakaganda, Annet, Ergin, Isil, Moraes, Fabio Ynoe, Timilshina, Nahari, Kumar, Ashutosh, Vale, Diama B., Molina-Barceló, Ana, Force, Lisa M., Campbell, Denise Joan, Wang, Yuqing, Wan, Fang, Baker, Anna Lisa, Singh, Ramnik, Salam, Rehana Abdus, Yuill, Susan, Shah, Richa, Lansdorp-Vogelaar, Iris, Yusuf, Aasim, Aggarwal, Ajay, Murillo, Raul, Torode, Julie S., Kliewer, Erich V., Bray, Freddie, Chan, Kelvin K.W., Peacock, Stuart, Hanna, Timothy P., Ginsburg, Ophira, Van Hemelrijck, Mieke, Sullivan, Richard, Roitberg, Felipe, Ilbawi, André M., Soerjomataram, Isabelle, and Canfell, Karen

Abstract

While previous reviews found a positive association between pre-existing cancer diagnosis and COVID-19-related death, most early studies did not distinguish long-term cancer survivors from those recently diagnosed/treated, nor adjust for important confounders including age. We aimed to consolidate higher-quality evidence on risk of COVID-19-related death for people with recent/active cancer (compared to people without) in the pre-COVID-19-vaccination period. We searched the WHO COVID-19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk-of-bias assessment was based on the Newcastle-Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse-variance random-effects models. Random-effects meta-regressions were used to assess associations between effect estimates and time since cancer diagnosis/treatment. Of 23 773 unique title/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID-19-related death was higher for people with active or recently diagnosed/treated cancer (general population: aOR = 1.48, 95% CI: 1.36-1.61, I2 = 0; people with COVID-19: aOR = 1.58, 95% CI: 1.41-1.77, I2 = 0.58; inpatients with COVID-19: aOR = 1.66, 95% CI: 1.34-2.06, I2 = 0.98). Risks were more elevated for lung (general population: aOR = 3.4, 95% CI: 2.4-4.7) and hematological cancers (general population: aOR = 2.13, 95% CI: 1.68-2.68, I2 = 0.43), and for metastatic cancers. Meta-regression suggested risk of COVID-19-related death decreased with time since diagnosis/treatment, for example, for any/solid cancers, fitted aOR = 1.55 (95% CI: 1.37-1.75) at 1 year and aOR = 0.98 (95% CI: 0.80-1.20) at 5 years post-cancer diagnosis/treatment. In conclusion, before CO

Published
2024

4. Sequential Acquisition of Human Papillomavirus Infection at Genital and Anal Sites, Liuzhou, China

Author

Wei, Feixue, Su, Yingying, Cui, Xuelian, Yu, Xiaojuan, Li, Yafei, Song, Qiaoqiao, Yin, Kai, Huang, Shoujie, Li, Mingqiang, Zhang, Jun, Wu, Ting, and Xia, Ningshao

Subjects
Papillomavirus infections, Health
Abstract

Oncogenic human papillomavirus (HPV) infection can cause cancers at the anogenital site (1-3). Globally, HPV-attributable anogenital cancers include [approximately equal to] 570,000 cervical, 8,500 vulvar, 12,000 vaginal, 13,000 penile, and [...]

Published
2020
Full Text
View/download PDF

5. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women

Author

Hu, Yue-Mei, Guo, Meng, Li, Chang-Gui, Chu, Kai, He, Wen-Gang, Zhang, Jing, Gu, Jian-Xiang, Li, Juan, Zhao, Hui, Wu, Xiang-Hong, Lin, BiZhen, Lin, Zhi-Jie, Yao, Xing-Mei, Li, Ya-Fei, Wei, FeiXue, Huang, Yue, Su, Ying-Ying, Zhu, Feng-Cai, Huang, Shou-Jie, Pan, Hui-Rong, Wu, Ting, Zhang, Jun, and Xia, Ning-Shao

Published
2020
Full Text
View/download PDF

6. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women

Author

Hu, YueMei, Guo, Meng, Li, ChangGui, Chu, Kai, He, WenGang, Zhang, Jing, Gu, JianXiang, Li, Juan, Zhao, Hui, Wu, XiangHong, Lin, BiZhen, Lin, ZhiJie, Yao, XingMei, Li, YaFei, Wei, FeiXue, Huang, Yue, Su, YingYing, Zhu, FengCai, Huang, ShouJie, Pan, HuiRong, Wu, Ting, Zhang, Jun, and Xia, NingShao

Abstract

A new HPV-16/18 bivalent vaccine expressed by the Escherichia colihas been proven to be efficacious in adult women. A randomized, immunogenicity noninferiority study of this candidate vaccine was conducted in December 2015 in China. Girls aged 9–14 years were randomized to receive 2 doses at months 0 and 6 (n=301) or 3 doses at months 0, 1 and 6 (n=304). Girls aged 15–17 years (n=149) and women aged 18–26 years (n=225) received 3 doses. The objectives included noninferiority analysis of the IgG geometric mean concentration (GMC) ratio (95% CI, lower bound>0.5) to HPV-16 and HPV-18 at month 7 in girls compared with women. In the per-protocol set, the GMC ratio of IgG was noninferior for girls aged 9–17 years receiving 3 doses compared with women (1.76 (95% CI, 1.56, 1.99) for HPV-16 and 1.93 (95% CI, 1.69, 2.21) for HPV-18) and noninferior for girls aged 9–14 years receiving 2 doses compared with women (1.45 (95% CI, 1.25, 1.62) for HPV-16 and 1.17 (95% CI, 1.02, 1.33) for HPV-18). Noninferiority was also demonstrated for neutralizing antibodies. The immunogenicity of the HPV vaccine in girls receiving 3 or 2 doses was noninferior compared with that in young adult women.

Published
2024
Full Text
View/download PDF

7. Comparison of detection strategies for screening and confirming congenital cytomegalovirus infection in newborns in a highly seroprevalent population: a mother-child cohort study

Author

Huang, Yue, primary, Wang, Han, additional, Li, Tingdong, additional, Li, Caihong, additional, Tang, Jiabao, additional, Yu, Huan, additional, Guo, Xiaoyi, additional, Song, Qiaoqiao, additional, Wei, Feixue, additional, Wang, Jiangding, additional, Liang, Caihong, additional, Zheng, Fengxian, additional, Li, Hongjuan, additional, Li, Huifeng, additional, Wu, Hongguo, additional, Lu, Zhaoxin, additional, Su, Yingying, additional, Wu, Ting, additional, Ge, Shengxiang, additional, Fu, Tong-Ming, additional, Zhang, Jun, additional, and Xia, Ningshao, additional

Published
2021
Full Text
View/download PDF

8. Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies

Author

Wei, Feixue, Gaisa, Michael M., D'Souza, Gypsyamber, Xia, Ningshao, Giuliano, Anna R., Hawes, Stephen E., Gao, Lei, Cheng, Shu-Hsing, Dona, Maria Gabriella, Goldstone, Stephen E., van der Loeff, Maarten F. Schim, Neukam, Karin, Meites, Elissa, Poynten, I. Mary, Dai, Jianghong, Combes, Jean-Damien, Wieland, Ulrike, Burgos, Joaquin, Wilkin, Timothy J., Hernandez, Alexandra L., Diaz, Mauricio Iribarren, Hidalgo-Tenorio, Carmen, Arredondo, Marleny Valencia, Nyitray, Alan G., Wentzensen, Nicolas, Chow, Eric Pf, Smelov, Vitaly, Nowak, Rebecca G., Phanuphak, Nittaya, Woo, Yin Ling, Choi, Yoojin, Hu, Yifei, Schofield, Alice M., Woestenberg, Petra J., Chikandiwa, Admire T., Hickey, Andrew C., de Pokomandy, Alexandra, Murenzi, Gad, Pere, Helene, del Pino, Marta, Ortiz, Ana P., Charnot-Katsikas, Angella, Liu, Xing, Chariyalertsak, Suwat, Strong, Carol, Ong, Jason J., Yunihastuti, Evy, Etienney, Isabelle, Ferre, Valentine M., Zou, Huachun, Segondy, Michel, Chinyowa, Simbarashe, Alberts, Catharina J., Clifford, Gary M., Wei, Feixue, Gaisa, Michael M., D'Souza, Gypsyamber, Xia, Ningshao, Giuliano, Anna R., Hawes, Stephen E., Gao, Lei, Cheng, Shu-Hsing, Dona, Maria Gabriella, Goldstone, Stephen E., van der Loeff, Maarten F. Schim, Neukam, Karin, Meites, Elissa, Poynten, I. Mary, Dai, Jianghong, Combes, Jean-Damien, Wieland, Ulrike, Burgos, Joaquin, Wilkin, Timothy J., Hernandez, Alexandra L., Diaz, Mauricio Iribarren, Hidalgo-Tenorio, Carmen, Arredondo, Marleny Valencia, Nyitray, Alan G., Wentzensen, Nicolas, Chow, Eric Pf, Smelov, Vitaly, Nowak, Rebecca G., Phanuphak, Nittaya, Woo, Yin Ling, Choi, Yoojin, Hu, Yifei, Schofield, Alice M., Woestenberg, Petra J., Chikandiwa, Admire T., Hickey, Andrew C., de Pokomandy, Alexandra, Murenzi, Gad, Pere, Helene, del Pino, Marta, Ortiz, Ana P., Charnot-Katsikas, Angella, Liu, Xing, Chariyalertsak, Suwat, Strong, Carol, Ong, Jason J., Yunihastuti, Evy, Etienney, Isabelle, Ferre, Valentine M., Zou, Huachun, Segondy, Michel, Chinyowa, Simbarashe, Alberts, Catharina J., and Clifford, Gary M.

Abstract

Background Robust age-specific estimates of anal human papillomavirus (HPV) and high-grade squamous intraepithelial lesions (HSIL) in men can inform anal cancer prevention efforts. We aimed to evaluate the age-specific prevalence of anal HPV, HSIL, and their combination , in men, stratified by HIV status and sexuality. Methods We did a systematic review for studies on anal HPV infection in men and a pooled analysis of individual-level data from eligible studies across four groups: HIV-positive men who have sex with men (MSM), HIV-negative MSM, HIV-positive men who have sex with women (MSW), and HIV-negative MSW. Studies were required to inform on type-specific HPV infection (at least HPV16), detected by use of a PCR-based test from anal swabs, HIV status, sexuality (MSM, including those who have sex with men only or also with women, or MSW), and age. Authors of eligible studies with a sample size of 200 participants or more were invited to share deidentified individual-level data on the above four variables. Authors of studies including 40 or more HIV-positive MSW or 40 or more men from Africa (irrespective of HIV status and sexuality) were also invited to share these data. Pooled estimates of anal high-risk HPV (HR-HPV, including HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), and HSIL or worse (HSIL+), were compared by use of adjusted prevalence ratios (aPRs) from generalised linear models. Findings The systematic review identified 93 eligible studies, of which 6 4 contributed data on 29 900 men to the pooled analysis. Among HIV-negative MSW anal HPV16 prevalence was 1.8% (91 of 5190) and HR-HPV prevalence was 6.9% (345 of 5003); among HIV-positive MSW the prevalences were 8.7% (59 of 682) and 26.9% (179 of 666); among HIV-negative MSM they were 13.7% (1455 of 10 617) and 41.2% (3798 of 9215), and among HIV-positive MSM 28.5% (3819 of 13 411) and 74.3% (8765 of 11 803). In HIV-positive MSM, HPV16 prevalence was 5.6% (two of 36) among those age 15-18 ye

Published
2021

9. Age‐specific burden of cervical cancer associated with HIV: a global analysis with a focus on sub‐Saharan Africa

Author

Ibrahim Khalil, Ahmadaye;Mpunga, Tharcisse;Wei, Feixue;Baussano, Iacopo;Martel, Catherine;Bray, Freddie;Stelzle, Dominik;Dryden‐Peterson, Scott;Jaquet, Antoine;Horner, Marie‐Josèphe;Awolude, Olutosin A;Trejo, Mario Jesus;Mudini, Washington;Soliman, Amr S.;Sengayi‐Muchengeti, Mazvita;Coghill, Anna E.;Aardt, Matthys C;De Vuyst, Hugo;Hawes, Stephen E;Broutet, Nathalie;Dalal, Shona;Clifford, Gary M and Ibrahim Khalil, Ahmadaye;Mpunga, Tharcisse;Wei, Feixue;Baussano, Iacopo;Martel, Catherine;Bray, Freddie;Stelzle, Dominik;Dryden‐Peterson, Scott;Jaquet, Antoine;Horner, Marie‐Josèphe;Awolude, Olutosin A;Trejo, Mario Jesus;Mudini, Washington;Soliman, Amr S.;Sengayi‐Muchengeti, Mazvita;Coghill, Anna E.;Aardt, Matthys C;De Vuyst, Hugo;Hawes, Stephen E;Broutet, Nathalie;Dalal, Shona;Clifford, Gary M

Published
2021

10. Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies

Author

International Agency for Research on Cancer, Wei, Feixue, Gaisa, Michael M., D’Souza, Gypsyamber, Xia, Ningshao, Giuliano, Anna R., Hawes, Stephen E., Gao, Lei, Cheng, Shu-Hsing, Donà, María Gabriella, Goldstone, Stephen E., Schim van der Loeff, Maarten F., Neukam, Karin, Meites, Elissa, Poynten, Mary, Dai, Jianghong, Combes, Jean-Damien, Wieland, Ulrike, Burgos, Joaquín, Wilkin, Timothy J., Hernandez, Alexandra L., Iribarren Díaz, Mauricio, Hidalgo-Tenorio, Carmen, Valencia Arredondo, Marleny, Nyitray, Alan G, Wentzensen, Nicolas, Chow, Eric PF, Smelov, Vitaly, Nowak, Rebecca G ., Phanuphak, Nittaya, Woo, Yin Ling, Choi, Yoojin, Hu, Yifei, Schofield, Alice M., Woestenberg, Petra J., Chikandiwa, Admire T., Hickey, Andrew C, Pokomandy, Alexandra de, Murenzi, Gad, Péré, Hélène, Pino, Marta del, Ortiz, Ana P., Charnot-Katsikas, Angella, Liu, Xing, Chariyalertsak, Suwat, Strong, Carol, Ong, Jason J., Yunihastuti, Evy, Etienney, Isabelle, Ferré, Valentine M., Zou, Huachun, Segondy, Michel, Chinyowa, Simbarashe, Alberts, Catharina J., Clifford, Gary M., International Agency for Research on Cancer, Wei, Feixue, Gaisa, Michael M., D’Souza, Gypsyamber, Xia, Ningshao, Giuliano, Anna R., Hawes, Stephen E., Gao, Lei, Cheng, Shu-Hsing, Donà, María Gabriella, Goldstone, Stephen E., Schim van der Loeff, Maarten F., Neukam, Karin, Meites, Elissa, Poynten, Mary, Dai, Jianghong, Combes, Jean-Damien, Wieland, Ulrike, Burgos, Joaquín, Wilkin, Timothy J., Hernandez, Alexandra L., Iribarren Díaz, Mauricio, Hidalgo-Tenorio, Carmen, Valencia Arredondo, Marleny, Nyitray, Alan G, Wentzensen, Nicolas, Chow, Eric PF, Smelov, Vitaly, Nowak, Rebecca G ., Phanuphak, Nittaya, Woo, Yin Ling, Choi, Yoojin, Hu, Yifei, Schofield, Alice M., Woestenberg, Petra J., Chikandiwa, Admire T., Hickey, Andrew C, Pokomandy, Alexandra de, Murenzi, Gad, Péré, Hélène, Pino, Marta del, Ortiz, Ana P., Charnot-Katsikas, Angella, Liu, Xing, Chariyalertsak, Suwat, Strong, Carol, Ong, Jason J., Yunihastuti, Evy, Etienney, Isabelle, Ferré, Valentine M., Zou, Huachun, Segondy, Michel, Chinyowa, Simbarashe, Alberts, Catharina J., and Clifford, Gary M.

Abstract

[Background] Robust age-specific estimates of anal human papillomavirus (HPV) and high-grade squamous intraepithelial lesions (HSIL) in men can inform anal cancer prevention efforts. We aimed to evaluate the age-specific prevalence of anal HPV, HSIL, and their combination, in men, stratified by HIV status and sexuality., [Methods] We did a systematic review for studies on anal HPV infection in men and a pooled analysis of individual-level data from eligible studies across four groups: HIV-positive men who have sex with men (MSM), HIV-negative MSM, HIV-positive men who have sex with women (MSW), and HIV-negative MSW. Studies were required to inform on type-specific HPV infection (at least HPV16), detected by use of a PCR-based test from anal swabs, HIV status, sexuality (MSM, including those who have sex with men only or also with women, or MSW), and age. Authors of eligible studies with a sample size of 200 participants or more were invited to share deidentified individual-level data on the above four variables. Authors of studies including 40 or more HIV-positive MSW or 40 or more men from Africa (irrespective of HIV status and sexuality) were also invited to share these data. Pooled estimates of anal high-risk HPV (HR-HPV, including HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), and HSIL or worse (HSIL+), were compared by use of adjusted prevalence ratios (aPRs) from generalised linear models., [Findings] The systematic review identified 93 eligible studies, of which 64 contributed data on 29 900 men to the pooled analysis. Among HIV-negative MSW anal HPV16 prevalence was 1·8% (91 of 5190) and HR-HPV prevalence was 6·9% (345 of 5003); among HIV-positive MSW the prevalences were 8·7% (59 of 682) and 26·9% (179 of 666); among HIV-negative MSM they were 13·7% (1455 of 10 617) and 41·2% (3798 of 9215), and among HIV-positive MSM 28·5% (3819 of 13 411) and 74·3% (8765 of 11 803). In HIV-positive MSM, HPV16 prevalence was 5·6% (two of 36) among those age 15–18 years and 28·8% (141 of 490) among those age 23–24 years (ptrend=0·0091); prevalence was 31·7% (1057 of 3337) among those age 25–34 years and 22·8% (451 of 1979) among those age 55 and older (ptrend<0·0001). HPV16 prevalence in HIV-negative MSM was 6·7% (15 of 223) among those age 15–18 and 13·9% (166 of 1192) among those age 23–24 years (ptrend=0·0076); the prevalence plateaued thereafter (ptrend=0·72). Similar age-specific patterns were observed for HR-HPV. No significant differences for HPV16 or HR-HPV were found by age for either HIV-positive or HIV-negative MSW. HSIL+ detection ranged from 7·5% (12 of 160) to 54·5% (61 of 112) in HIV-positive MSM; after adjustment for heterogeneity, HIV was a significant predictor of HSIL+ (aPR 1·54, 95% CI 1·36–1·73), HPV16-positive HSIL+ (1·66, 1·36–2·03), and HSIL+ in HPV16-positive MSM (1·19, 1·04–1·37). Among HPV16-positive MSM, HSIL+ prevalence increased with age., [Interpretation] High anal HPV prevalence among young HIV-positive and HIV-negative MSM highlights the benefits of gender-neutral HPV vaccination before sexual activity over catch-up vaccination. HIV-positive MSM are a priority for anal cancer screening research and initiatives targeting HPV16-positive HSIL+.

Published
2021

11. Cervical determinants of anal HPV infection and high-grade anal lesions in women : a collaborative pooled analysis

Author

Lin, Chunqing, Slama, Jiri, Gonzalez, Paula, Goodman, Marc T, Xia, Ningshao, Kreimer, Aimée R, Wu, Ting, Hessol, Nancy A, Shvetsov, Yurii, Ortiz, Ana P, Grinsztejn, Beatriz, Moscicki, Anna-Barbara, Heard, Isabelle, Del Refugio González Losa, María, Kojic, Erna M, Schim van der Loeff, Maarten F, Wei, Feixue, Longatto-Filho, Adhemar, Mbulawa, Zizipho A, Palefsky, Joel M, Sohn, Annette H, Hernandez, Brenda Y, Robison, Katina, Simpson, Steve, Conley, Lois J, de Pokomandy, Alexandra, van der Sande, Marianne A B, Dube Mandishora, Racheal S, Volpini, Lays P B, Pierangeli, Alessandra, Romero, Byron, Wilkin, Timothy, Franceschi, Silvia, Hidalgo-Tenorio, Carmen, Ramautarsing, Reshmie A, Park, Ina U, Tso, Fernanda K, Godbole, Sheela, D'Hauwers, Kathleen W M, Sehnal, Borek, Menezes, Lynette J, Heráclio, Sandra A, Clifford, Gary M, Lin, Chunqing, Slama, Jiri, Gonzalez, Paula, Goodman, Marc T, Xia, Ningshao, Kreimer, Aimée R, Wu, Ting, Hessol, Nancy A, Shvetsov, Yurii, Ortiz, Ana P, Grinsztejn, Beatriz, Moscicki, Anna-Barbara, Heard, Isabelle, Del Refugio González Losa, María, Kojic, Erna M, Schim van der Loeff, Maarten F, Wei, Feixue, Longatto-Filho, Adhemar, Mbulawa, Zizipho A, Palefsky, Joel M, Sohn, Annette H, Hernandez, Brenda Y, Robison, Katina, Simpson, Steve, Conley, Lois J, de Pokomandy, Alexandra, van der Sande, Marianne A B, Dube Mandishora, Racheal S, Volpini, Lays P B, Pierangeli, Alessandra, Romero, Byron, Wilkin, Timothy, Franceschi, Silvia, Hidalgo-Tenorio, Carmen, Ramautarsing, Reshmie A, Park, Ina U, Tso, Fernanda K, Godbole, Sheela, D'Hauwers, Kathleen W M, Sehnal, Borek, Menezes, Lynette J, Heráclio, Sandra A, and Clifford, Gary M

Published
2019

12. Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis

Author

Global Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Lin, Chunqing, Slama, Jiri, Gonzalez, Paula, Goodman, Marc T, Xia, Ningshao, Kreimer, Aimée R, Wu, Ting, Hessol, Nancy A, Shvetsov, Yurii, Ortiz, Ana P, Grinsztejn, Beatriz, Moscicki, Anna-Barbara, Heard, Isabelle, Del Refugio González Losa, María, Kojic, Erna M, Schim van der Loeff, Maarten F, Wei, Feixue, Longatto-Filho, Adhemar, Mbulawa, Zizipho A, Palefsky, Joel M, Sohn, Annette H, Hernandez, Brenda Y, Robison, Katina, Simpson, Steve, Conley, Lois J, de Pokomandy, Alexandra, van der Sande, Marianne A B, Dube Mandishora, Racheal S, Volpini, Lays P B, Pierangeli, Alessandra, Romero, Byron, Wilkin, Timothy, Franceschi, Silvia, Hidalgo-Tenorio, Carmen, Ramautarsing, Reshmie A, Park, Ina U, Tso, Fernanda K, Godbole, Sheela, D'Hauwers, Kathleen W M, Sehnal, Borek, Menezes, Lynette J, Heráclio, Sandra A, Clifford, Gary M, Global Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Lin, Chunqing, Slama, Jiri, Gonzalez, Paula, Goodman, Marc T, Xia, Ningshao, Kreimer, Aimée R, Wu, Ting, Hessol, Nancy A, Shvetsov, Yurii, Ortiz, Ana P, Grinsztejn, Beatriz, Moscicki, Anna-Barbara, Heard, Isabelle, Del Refugio González Losa, María, Kojic, Erna M, Schim van der Loeff, Maarten F, Wei, Feixue, Longatto-Filho, Adhemar, Mbulawa, Zizipho A, Palefsky, Joel M, Sohn, Annette H, Hernandez, Brenda Y, Robison, Katina, Simpson, Steve, Conley, Lois J, de Pokomandy, Alexandra, van der Sande, Marianne A B, Dube Mandishora, Racheal S, Volpini, Lays P B, Pierangeli, Alessandra, Romero, Byron, Wilkin, Timothy, Franceschi, Silvia, Hidalgo-Tenorio, Carmen, Ramautarsing, Reshmie A, Park, Ina U, Tso, Fernanda K, Godbole, Sheela, D'Hauwers, Kathleen W M, Sehnal, Borek, Menezes, Lynette J, Heráclio, Sandra A, and Clifford, Gary M

Published
2019

13. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women

Author

Hu, Yue-Mei, primary, Guo, Meng, additional, Li, Chang-Gui, additional, Chu, Kai, additional, He, Wen-Gang, additional, Zhang, Jing, additional, Gu, Jian-Xiang, additional, Li, Juan, additional, Zhao, Hui, additional, Wu, Xiang-Hong, additional, Lin, BiZhen, additional, Lin, Zhi-Jie, additional, Yao, Xing-Mei, additional, Li, Ya-Fei, additional, Wei, FeiXue, additional, Huang, Yue, additional, Su, Ying-Ying, additional, Zhu, Feng-Cai, additional, Huang, Shou-Jie, additional, Pan, Hui-Rong, additional, Wu, Ting, additional, Zhang, Jun, additional, and Xia, Ning-Shao, additional

Published
2019
Full Text
View/download PDF

14. An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency

Author

Shen, Chenguang, primary, Zhang, Minwei, additional, Chen, Yuanzhi, additional, Zhang, Limin, additional, Wang, Guosong, additional, Chen, Junyu, additional, Chen, Siyuan, additional, Li, Zizhen, additional, Wei, Feixue, additional, Chen, Jing, additional, Yang, Kunyu, additional, Guo, Shuxin, additional, Wang, Yujing, additional, Zheng, Qingbing, additional, Yu, Hai, additional, Luo, Wenxin, additional, Zhang, Jun, additional, Chen, Honglin, additional, Chen, Yixin, additional, and Xia, Ningshao, additional

Published
2019
Full Text
View/download PDF

15. Sequential Acquisition of Human Papillomavirus Infection at Genital and Anal Sites, Liuzhou, China.

Author

Feixue Wei, Yingying Su, Xuelian Cui, Xiaojuan Yu, Yafei Li, Qiaoqiao Song, Kai Yin, Shoujie Huang, Mingqiang Li, Jun Zhang, Ting Wu, Ningshao Xia, Wei, Feixue, Su, Yingying, Cui, Xuelian, Yu, Xiaojuan, Li, Yafei, Song, Qiaoqiao, Yin, Kai, and Huang, Shoujie

Abstract

Little is known about the risk for acquiring a concordant human papillomavirus (HPV) infection in a genital (or anal) site after an anal (or genital) HPV infection. We collected 3 sets of anogenital specimens at 6-month intervals from 2,309 men and 2,378 women in Liuzhou, China, and tested these specimens for HPV. The risk for sequential anal HPV infection in participants with a previous genital HPV infection was higher than for participants without an infection (hazard ratio [HR] 4.4, 95% CI 3.4-5.8 for women and HR 2.6, 95% CI 1.4-4.6 for men). For sequential genital HPV infection, women with a previous anal infection had a higher risk (HR 1.9, 95% CI 1.2-3.1), but no major difference was found for men (HR 0.7, 95% CI 0.2-1.9). Our study indicates that autoinoculation might play a major role in anogenital HPV transmission, in addition to direct sexual intercourse, especially for anal infection in women. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

16. Incidence of anogenital warts in Liuzhou, south China: a comparison of data from a prospective study and from the national surveillance system

Author

Wei, Feixue, primary, Sheng, Wei, additional, Wu, Xin, additional, Yin, Kai, additional, Lan, Jian, additional, Huang, Yue, additional, Ma, Xinjing, additional, Zheng, Ya, additional, Zhuang, Sijie, additional, Huang, Shoujie, additional, Su, Yingying, additional, Li, Mingqiang, additional, Wu, Ting, additional, Zhang, Jun, additional, and Xia, Ningshao, additional

Published
2017
Full Text
View/download PDF

17. Human papillomavirus prevalence and associated factors in women and men in south China: a population-based study

Author

Wei, Feixue, primary, Yin, Kai, additional, Wu, Xin, additional, Lan, Jian, additional, Huang, Shoujie, additional, Sheng, Wei, additional, Zhao, Jun, additional, Su, Yingying, additional, Wang, Ying, additional, Li, Yanping, additional, Li, Rongcheng, additional, Zhang, Jun, additional, Li, Mingqiang, additional, Wu, Ting, additional, and Xia, Ningshao, additional

Published
2016
Full Text
View/download PDF

18. Comparison of detection strategies for screening and confirming congenital cytomegalovirus infection in newborns in a highly seroprevalent population: a mother-child cohort study.

Author

Huang Y, Wang H, Li T, Li C, Tang J, Yu H, Guo X, Song Q, Wei F, Wang J, Liang C, Zheng F, Li H, Li H, Wu H, Lu Z, Su Y, Wu T, Ge S, Fu TM, Zhang J, and Xia N

Abstract

Background: Universal screening of congenital cytomegalovirus (cCMV) infection is important for monitoring and intervention during critical stages of speech and language development. This study aimed to explore the optimal detection strategy for cCMV infection screening., Methods: Serum samples from pregnant women and saliva and urine samples from their newborns were collected for the anti-CMV IgG and CMV DNA PCR tests, respectively. The sensitivity, specificity, and predictive values as well as the likelihood ratios of 12 potential screening strategies for cCMV infection, based on tests for saliva, urine, and their combination, were evaluated., Findings: A total of 6729 pregnant women were enrolled, and the seroprevalence was 98.1%. Among 6350 newborns that were followed up, 49 were defined as having cCMV infection. In the screening test, the CMV DNA positivity rate remained similar from day 0 to day 5, increased slowly from day 6 to day 13, and became high in newborns beyond 13 days of birth. In the confirmatory testing, the positive rates increased significantly beyond day 21. For the 49 newborns with cCMV infection, the proportion of agreement between saliva and urine testing was poor. Upon evaluating alternative screening strategies, using saliva and urine screening with saliva and urine confirmation as the reference strategy, saliva screening with saliva and urine confirmation showed good diagnostic accuracy and feasibility, with sensitivity, specificity, positive predictive and negative predictive values of 85.7%, 100.0%, 100.0% and 99.9%, respectively., Interpretation: In populations with high seroprevalence, saliva screening with saliva and urine confirmation might be an alternative strategy for screening cCMV infections. The suggested timeframes for screening and confirmation are within 13 (ideally 5) and 21 (ideally 13) days of birth, respectively., Funding: National Natural Science Foundation of China, National Science and Technology Major Project of China and Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., Competing Interests: Jun Zhang received grant from Merck & Co., Inc. during the conduct of the study. All other authors declare no competing interests., (© 2021 The Author(s). Published by Elsevier Ltd.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results